跳至主要内容
临床试验/NCT01440725
NCT01440725已完成3 期

Multicenter Double Blind, With Evaluator Blinding, Parallel, Randomized Clinical Trial, to Assess the Efficacy of Platelet Rich Plasma for Treatment of Muscle Rupture With Haematoma

Institut de Terapia Regenerativa Tissular2 个研究点 分布在 1 个国家目标入组 71 人开始时间: 2009年10月1日最近更新:
适应症

试验速览

阶段
3 期
状态
已完成
发起方
入组人数
71
试验地点
2
主要终点
Time to complete recover of muscular lesions

研究概览

简要总结

This is a multicenter, simple blind, masking of outcomes assessors, parallel, randomised clinical trial in patient with muscle rupture and with hematoma production. The main hypothesis is that infiltration in the area of muscle injury in autologous platelet-rich plasma (PRP)improves muscle regeneration and repair by shortening the time to complete recovery.

The main objective is to evaluate the PRP for healing muscular lesions 'tennis leg' type or distal rectus femoral. The secondary objectives are: to evaluate the risk of lesion recurrence; to evaluate the quality of lesion recovery process and evaluate intervention's safety.

Experimental treatment will be the administration of PRP autologous (4-8 cc in a unique dose) by muscular infiltration en the empty space generated after the hematoma evacuation. Control treatment will be hematoma evacuation. Both treatment groups will use compressive bandage and they will recommend rest, extremity elevation, local ice and lately physiotherapy.

Size sample: 76 patients (38 in each group)

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Double (Participant, Outcomes Assessor)

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Adults over 18 years
  • Lesion with haematoma at the Gastrocnemius muscle or the lower portion of the rectus femoral muscle
  • Acceptance to participate at the clinical trial
  • Not indicated the surgical treatment of the muscle injury

排除标准

  • Patients who do not meet the inclusion criteria
  • History of bleeding disorders
  • Inability to follow-up the patient
  • The use of corticosteroids, acetylsalicylic acid(Aspirin ®) and nonsteroidal antiinflammatory drugs during the study

结局指标

主要结局

Time to complete recover of muscular lesions

时间窗: weekely assessment during 8 weeks

The complete recovering will be when the patient does his habitual activity.

次要结局

  • Percentage of muscular lesion recurrence.(During all study (one year of follow-up))
  • Percentage of healing(8 weeks)
  • Quality of the regenerated area(at 8 week)
  • Pain(12 months)
  • Adverse effects to treatments(12 months)

研究者

发起方
Institut de Terapia Regenerativa Tissular
申办方类型
Other
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验

招募中
不适用
Tennis Elbow Acupuncture International Study - China, Hong Kong, Australia and ItalyTendinosis of the common extensor carpi radialis brevis tendon commonly called tennis elbow or lateral epicondylitisMusculoskeletal - Other muscular and skeletal disordersAlternative and Complementary Medicine - Other alternative and complementary medicine
ACTRN12613001138774niversity of Technology, Sydney96
进行中(未招募)
1 期
Study of a new drug’s effect in people with severe rheumatoid arthritis who have not responded sufficiently well to treatment with DMARDsRheumatoid Arthritis (RA)MedDRA version: 20.0Level: PTClassification code 10039073Term: Rheumatoid arthritisSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disorders
EUCTR2015-005800-27-PLGlaxoSmithKline Research & Development Ltd40
已完成
3 期
Clinical Trial of YYD701-2 for Treatment of Nasolabial FoldsWrinkle Severity Rating Scale(WSRS) Grade 3 (Moderate) or 4 (Severe) of Nasolabial Folds
NCT03170050Yooyoung Pharmaceutical Co., Ltd.107
进行中(未招募)
不适用
A multicenter, randomized, double-blind, assessor-blind, non-inferiority study comparing the efficacy and safety of once-weekly subcutaneous biotinylated idraparinux (SSR126517E) with oral adjusted-dose warfarin in the prevention of stroke and systemic thromboembolic events in patients with atrial fibrillation - BOREALIS-AFThe subjects who will participate to this clinical trial are not healthy volonteers.They have Permanent, persistent or paroxysmal non-valvular atrial fibrillation that is ECG-documented, with an indication for long-term VKA therapy.
EUCTR2007-004817-33-PTsanofi-aventis recherche&développement9,600
Unknown
3 期
A clinical trial to study the safety and efficacy of a new drug biotinylated idraparinux (SSR126517E) as compared to another drug warfarin in the prevention of stroke and systemic thromboembolic events in patients with atrial fibrillatio
CTRI/2008/091/000018SanofiSynthelabo India Limited9,600